Marmé, Frederik <br/><br/>
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.  [electronic resource] 

 -  Breast cancer research and treatment  Apr 2012 
 - 819-31 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-011-1759-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amino Acid Substitution<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Breast Neoplasms--drug therapy<br/>CD24 Antigen--genetics<br/>Cell Line, Tumor<br/>Cyclophosphamide--administration & dosage<br/>Docetaxel<br/>Doxorubicin--administration & dosage<br/>Female<br/>Genotype<br/>Glutamates--administration & dosage<br/>Guanine--administration & dosage<br/>Humans<br/>Leukocyte Common Antigens--metabolism<br/>Lymphocytes--metabolism<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Invasiveness<br/>Pemetrexed<br/>Polymorphism, Genetic<br/>Sequence Analysis, DNA<br/>Statistics, Nonparametric<br/>Taxoids--administration & dosage<br/>Treatment Outcome